Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HIV vaccine - GeneCure

Drug Profile

HIV vaccine - GeneCure

Alternative Names: HIVAX; Replication-defective HIV-1 vaccine (HIVAX™) - GeneCure Biotechnologies

Latest Information Update: 28 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GeneCure
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported HIV-1 infections

Most Recent Events

  • 28 Apr 2018 No recent reports of development identified for phase-I development in HIV-1-infections in USA (Parenteral)
  • 01 Apr 2016 Phase-I development is ongoing in USA
  • 13 May 2015 Interim efficacy and adverse events data from a phase I trial in HIV-1 infections released by Genecure
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top